188 related articles for article (PubMed ID: 31401673)
1. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.
Pak S; Kim W; Kim Y; Song C; Ahn H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2293-2301. PubMed ID: 31401673
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway.
Song C; Kim Y; Min GE; Ahn H
Prostate; 2014 Sep; 74(12):1240-8. PubMed ID: 25043756
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
Jang YG; Go RE; Hwang KA; Choi KC
J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
[TBL] [Abstract][Full Text] [Related]
4. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation.
Yu CP; Ho JY; Huang YT; Cha TL; Sun GH; Yu DS; Chang FW; Chen SP; Hsu RJ
PLoS One; 2013; 8(2):e56667. PubMed ID: 23460808
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.
Chen Y; Sun Y; Rao Q; Xu H; Li L; Chang C
Oncotarget; 2015 Oct; 6(31):31203-15. PubMed ID: 26304926
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
8. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
9. Intracrine androgen biosynthesis in renal cell carcinoma.
Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY
Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling.
Guan Z; Li C; Fan J; He D; Li L
Sci Rep; 2016 Nov; 6():37085. PubMed ID: 27848972
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.
Izumi K; Zheng Y; Li Y; Zaengle J; Miyamoto H
Int J Oncol; 2012 Nov; 41(5):1587-92. PubMed ID: 22922989
[TBL] [Abstract][Full Text] [Related]
12. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening.
Hartig PC; Bobseine KL; Britt BH; Cardon MC; Lambright CR; Wilson VS; Gray LE
Toxicol Sci; 2002 Mar; 66(1):82-90. PubMed ID: 11861975
[TBL] [Abstract][Full Text] [Related]
13. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
14. C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.
Yue D; Wang Y; Sun Y; Niu Y; Chang C
Neoplasia; 2017 Feb; 19(2):135-144. PubMed ID: 28107702
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
16. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
[TBL] [Abstract][Full Text] [Related]
17. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract][Full Text] [Related]
18. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
19. CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway.
Peng L; He K; Cao Z; Bi L; Yu D; Wang Q; Wang J
Mol Med Rep; 2020 Jan; 21(1):329-337. PubMed ID: 31939627
[TBL] [Abstract][Full Text] [Related]
20. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
